- Home
- ANNX vs RXT Comparison
ANNX vs RXT Comparison
Compare ANNX & RXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- RXT
- Stock Information
- Founded
- ANNX 2011
- RXT 1998
- Country
- ANNX United States
- RXT United States
- Employees
- ANNX N/A
- RXT N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- RXT EDP Services
- Sector
- ANNX Health Care
- RXT Technology
- Exchange
- ANNX Nasdaq
- RXT Nasdaq
- Market Cap
- ANNX 263.3M
- RXT 314.5M
- IPO Year
- ANNX 2020
- RXT 2020
- Fundamental
- Price
- ANNX $2.42
- RXT $1.23
- Analyst Decision
- ANNX Strong Buy
- RXT Hold
- Analyst Count
- ANNX 4
- RXT 4
- Target Price
- ANNX $12.50
- RXT $1.63
- AVG Volume (30 Days)
- ANNX 1.7M
- RXT 934.5K
- Earning Date
- ANNX 08-11-2025
- RXT 08-07-2025
- Dividend Yield
- ANNX N/A
- RXT N/A
- EPS Growth
- ANNX N/A
- RXT N/A
- EPS
- ANNX N/A
- RXT N/A
- Revenue
- ANNX N/A
- RXT $2,711,700,000.00
- Revenue This Year
- ANNX N/A
- RXT N/A
- Revenue Next Year
- ANNX N/A
- RXT $1.48
- P/E Ratio
- ANNX N/A
- RXT N/A
- Revenue Growth
- ANNX N/A
- RXT N/A
- 52 Week Low
- ANNX $1.29
- RXT $1.00
- 52 Week High
- ANNX $7.85
- RXT $3.41
- Technical
- Relative Strength Index (RSI)
- ANNX 47.32
- RXT 44.88
- Support Level
- ANNX $2.29
- RXT $1.15
- Resistance Level
- ANNX $2.62
- RXT $1.51
- Average True Range (ATR)
- ANNX 0.17
- RXT 0.11
- MACD
- ANNX -0.01
- RXT -0.03
- Stochastic Oscillator
- ANNX 37.74
- RXT 26.19
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.